Evolus, Inc. — FY 2023 Form 10-K
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2023, not a standalone Q4 report. Evolus sells Jeuveau, an injectable neurotoxin for frown lines, and generated all net revenue from Jeuveau in 2023. Evolysse, a dermal-filler portfolio, remained in development. The supplied filing text does not provide clear standalone Q4 financial results.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net revenue | $202.1 million | $148.6 million |
| Gross profit | $137.6 million | $89.8 million |
| Gross margin | 68.1% | 60.4% |
| Operating loss | $49.2 million | $65.3 million |
| Net loss | $61.7 million | $74.4 million |
| Net loss per share, diluted | $1.08 | $1.33 |
| Cash used in operating activities | $34.0 million | $84.9 million |
- Revenue grew 36.0%, primarily on higher Jeuveau sales volume. Product revenue was $199.7 million; Canadian distribution service revenue was $2.4 million.
- SG&A rose 16.3% to $164.9 million, mainly from personnel and commercial activity. R&D was $6.6 million; in-process R&D was $8.9 million.
- At year-end, cash and cash equivalents were $62.8 million and working capital was $64.1 million. Total liabilities were $209.7 million, against assets of $189.0 million; stockholders’ deficit was $20.7 million.
- Term-loan carrying value was $120.4 million, with $125.0 million principal outstanding. The variable rate is three-month SOFR, subject to a 1.0% floor, plus 8.5%; interest-only payments continue until March 2026. The debt is secured by substantially all company assets.
Material changes versus FY 2022
- Gross margin increased 7.7 percentage points. The filing attributes the improvement in part to the end of Allergan royalties and the reduction in Medytox royalties after September 2022; a mid-single-digit royalty on Jeuveau net sales remains payable through September 2032.
- Net and operating losses narrowed, while operating cash use fell by $50.9 million. The prior-year cash use included a $15 million settlement payment; 2023 included the final $5 million payment. A $50 million second loan tranche provided financing cash in 2023.
- Cash increased by $8.9 million to $62.8 million. The company also issued 610,000 shares to Symatese for European Evolysse rights.
Outlook, commentary, and risks
- Management expects current capital resources and expected cash generation to fund operations for at least 12 months from issuance of the financial statements. The filing also expects operating losses and negative operating cash flow to continue for at least the next 12 months; additional financing may be needed for longer-term needs.
- Management expected European approval of remaining Evolysse products in late 2024, U.S. approval and initial launches beginning in 2025, and later launches in 2026–2027. These are expectations, not guarantees; Symatese is responsible for obtaining regulatory approvals.
- Jeuveau’s commercialization depends on a single product, faces established competitors, and is exposed to discretionary consumer spending. Evolus relies on Daewoong as its sole Jeuveau manufacturer and Symatese for Evolysse supply and regulatory development. Minimum purchases and market performance affect exclusivity under these agreements.
- Other material risks include the Medytox royalty burden, variable-rate debt, potential financing needs, inflation and interest rates, regulatory delays, product liability and intellectual-property disputes, and cybersecurity or supply interruptions.
- Pending securities class-action and shareholder derivative matters remain unresolved. Management could not reasonably estimate a loss range. The filing reports no amounts accrued for these matters at year-end.
- Auditors issued an unqualified opinion on the financial statements and on internal control over financial reporting. A critical audit matter was the valuation of the founders’ contingent royalty obligation, which depends on projected Jeuveau revenue and other unobservable assumptions.
Important facts for investors to verify
- Latest Jeuveau sales trends, customer retention, discounting, and whether revenue growth translates into improved operating cash flow.
- Progress and timing of Evolysse regulatory approvals, launches, spending, milestone payments, and required minimum purchases.
- Cash runway under updated operating assumptions, loan interest costs, repayment schedule, and any need to use the unused $50 million ATM program.
- Impact of Medytox and founder royalties on future gross margins and cash obligations.
- Developments in the pending shareholder litigation and any changes to the risk or estimated financial exposure.